Endo and Impax had non-compete agreement, FTC says

A lower court mischaracterised an agreement between Endo Pharmaceuticals and Impax Laboratories to forgo competition over a painkiller as a valid patent licensing agreement, the Federal Trade Commission has argued on appeal before the US Court of Appeals for the District of Columbia Circuit.

Unlock unlimited access to all Global Competition Review content